Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis.
Ingmar
I
Mederacke
Torsten
T
Witte
Heiner
H
Wedemeyer
Dirk
D
Meyer-Olson
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D000068800:Etanercept; D019694:Hepatitis B, Chronic / Q000150:complications; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D055985:Latent Tuberculosis / Q000150:complications; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000068800:Etanercept; C100416:peginterferon alfa-2a